VYVGART HYTRULO

Growth

efgartigimod alfa and hyaluronidase-qvfc

BLAINJECTIONINJECTABLEPriority Review

Approved

Jun 2023

Lifecycle

Growth

Competitive Pressure

30/100

Mechanism of Action

Neonatal Fc Receptor Blockers

Pharmacologic Class:

Endoglycosidase

Company

Belgium - Zwijnaarde

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers